Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saxagliptin + dapagliflozin + metformin versus glimepiride + metformin in adults with inadequately controlled type 2 diabetes mellitus
2014-003721-18Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- May 2015
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Saxagliptin + dapagliflozin + metformin with Glimepiride + metformin (2 arms). Primary endpoint: Change from baseline in HbA1c at Week 52. Started May 2015; status: completed.
02
Drugs
saxagliptindapagliflozinglimepiridemetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2014-003721-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003721-18.